Abstract
The current 14-day randomised placebo-controlled trial in 53 men with schizophrenia was conducted to evaluate the efficacy of 2 mg oral estradiol valerate as an adjunct to atypical antipsychotic treatment. Results demonstrated for estradiol participants a more rapid reduction in general psychopathology that occurred in the context of greater increases in serum estrogen levels and reductions in FSH and testosterone levels
Original language | English |
---|---|
Pages (from-to) | 278 - 283 |
Number of pages | 5 |
Journal | Schizophrenia Research |
Volume | 125 |
DOIs | |
Publication status | Published - 2011 |